This video from BBC documents the latest pioneering in stem cell applications as surgeons in the UK test a new treatment for age-related macular degeneration following 10 years of intensive development. The trial results are ongoing. The video is embedded below, with key points to take away from this groundbreaking trial treatment. [Read more…]
Cynata Receives Favourable Advice from UK Regulatory Authority – Prepares to Initiate Clinical Trial of 1st Allogenic iPSC-derived MSC Product
In major news released today, Cynata Therapeutics announced that it had received favorable advice from the UK regulatory authority, a step forward in the development of its proprietary Cymerus™ therapeutic mesenchymal stem cell (MSC) technology. This input from the UK regulatory authority (MHRA) will allow Cynata to proceed with its plans to conduct a Phase 1 clinical trial in graft-versus-host disease in the UK. It also gives Cynata a clear path forward to commence the clinical development program of this valuable technology.
Formal meetings with other national regulatory bodies are scheduled within the coming weeks, the outcome of which will allow Cynata to consider further jurisdictions for the trial. The trial remains on track to commence during the second quarter of 2016. [Read more…]
Human Longevity Inc. Expands Role in Newborn Genome Sequencing with Strategic Acquisition of LifebankUSA from Celgene
In major news released today, Human Longevity, Inc. (HLI) announced that is is acquiring LifebankUSA, a cord blood, placental blood, and tissue bank owned by Celegene Cellular Therapeutics, a move that will position HLI to offer its newborn genome sequencing product in combination with stem cell banking services.
To learn more about the acquisition, read the full press release from Human Longevity, Inc. below.
Or, read our recent article exploring how this move will provide HLI with increased access to prenatal, neonatal, and maternal health markets, similar to the access that AMAG Pharmaceutical gained through its acquisition of Cord Blood Registry and PerkinElmer gained through its acquisition of ViaCord. [Read more…]
Human Longevity, Inc. to Expand Reach into Neonatal & Maternal Health Markets by Acquiring Celgene Owned LifebankUSA
In major news released today, Human Longevity, Inc. (HLI) announced that is is acquiring LifebankUSA, a cord blood, placental blood, and tissue bank owned by Celgene Cellular Therapeutics.
Based in San Diego, CA, Human Longevity, Inc. is an innovative company that specializes in the use of whole genome sequence analysis, clinical imaging, and machine learning to extend health across a longer human lifespan. LifebankUSA, based in Cedar Knolls, NJ, is the “the only company that offers cord blood, placenta blood and tissue banking – and the first to release placenta-derived stem cells for a successful transplant.” Celgene Cellular Therapeutics (CCT), the parent company of LifeBankUSA, specializes in cell therapy and regenerative medicine products, using LifeBankUSA to source its cell therapy, organ and tissue products, several of which are now being explored in clinical trials (PDA001, PDA002, and others).
The move will position Human Longevity, Inc. to offers its newborn genome sequencing product in combination to its newly acquired stem cell banking services.
[Read more…]
Roslin Cells to Create Two Specialized Subsidiaries – Roslin Cell Therapies and Roslin Cell Sciences
Established in Edinburgh, UK, in 2006, Roslin Cells has spent the last decade developing into a leader in the “development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).” With major facilities in both Edinburgh and Cambridge, the company can produce large volumes of cell lines from different donors, allowing pharmaceutical researchers to assess how drug performance can differ from individual to individual.
On January 11th, 2016, Roslin Cells announced major news that it is creating two subsidiary companies, one to facilitate “process development and manufacture of cell therapies for clinical trials” and the other to “focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery.” This will strengthen Roslin Cell’s position as a leader in both clinical-grade cell manufacturing and in iPSC production for drug discovery applications. [Read more…]
- « Previous Page
- 1
- …
- 272
- 273
- 274
- 275
- 276
- …
- 309
- Next Page »